YY received research funding from Chugai, Kyowa Kirin, Eisai, Daiichi Sankyo, Nippon-Kayaku, Taiho, Takeda, Eli Lilly, Pfizer, and Novartis; received honoraria from AstraZeneca, Chugai, Kyowa Kirin, Novartis, Eli Lilly, Pfizer, Daiichi Sankyo, Nippon-Kayaku, Taiho, Eisai, Takeda, MSD, Sysmex, and Exact Science; participated on a Data Safety Monitoring Board or Advisory Board of AstraZeneca, Chugai, Novartis, MSD, Eli Lilly, Pfizer, and Daiichi Sankyo; and is a member of the Board of Director of Japanese Breast Cancer Society and Japan Breast Cancer Research Group. TT received honoraria for lectures from Pfizer, Daiichi Sankyo, MSD, Lilly, Novartis, Taiho and Chugai. SN received honoraria from Eli Lilly, Pfizer, Chugai, Taiho, Eisai, MSD, Daiichi Sankyo, and AstraZeneca. TS received honoraria from Chugai, General Electric Company, Exact Science, Canon, and Ethicon. GK received honoraria from Lilly, Kyowa Kirin, Daiichi Sankyo, AstraZeneca Pfizer, and Chugai. MK received honoraria for lectures from AstraZeneca, Chugai, Eisai, Eli Lilly and Company, Kyowa Kirin, MSD, Novartis, and Pfizer. SO received honoraria for lectures from AstraZeneca, Chugai, Eisai and Eli Lilly. KK received honoraria from Lilly Medthech and Chugai. KN received grant from Daiichi Sankyo and received honoraria from GE Healthcare, Kyowa Kirin, Nippon-Kayaku and Fujifilm Healthcare. NH received honoraria for lecture from Daiichi Sankyo, and participated on an advisory board Roche Diagnostics Japan. M Yoshida received consulting fees from Lilly Japan, Roche Diagnostics; received honoraria from Agillent technologies, Chugai, MSD, Ono, and Daiichi Sankyo. ET received honoraria from Eli Lilly, Daiichi Sankyo, Astra Zeneca and Chugai. NT received grant from Esai and received honoraria from Pfizer. HI received grants from Chugai, Daiichi Sankyo, and AstraZeneca; consulting fees from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, and Giliead; and honoraria from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, Taiho, and Kyowa Kirin. SS received research funding from Taiho, Eisai, Chugai, Takeda, MSD, AstraZeneca, and Daiichi Sankyo; received honoraria from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Ono, and Nippon-Kayaku; participated on a Data Safety Monitoring Board or Advisory Board of Chugai/Roche, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD; is an executive member of JBCRG, JBCS, JSMO, and BIG. CY and M Yoshimura have no conflict of interests.

Not applicable.